Clinical Pharmacy Articles

Demands that clinical trials produce more safety and economic data threaten to drive drug development costs higher.

For full article Click Here

H. Remington, MPharm, MRPharmS
Hospital Pharmacist Vol 7 No 4 p107-108
April 2000

Efforts to ensure the safety and integrity of clinical trials will generate new standards and expand oversight initiatives.

For full article Click Here

Pharmaceutical companies and contract research organizations are setting up an increasing number of clinical trials in Central and Eastern Europe.

For full article Click Here

Even as the EU implementation deadline looms, clear clinical trial definitions remain elusive.

For full article Click Here

Robert W. Sutherst
Clinical Microbiology Reviews, January 2004, p. 136-173, Vol. 17, No. 1
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Clinical Review

As well as being a committed European, Domenico Criscuolo is a powerful supporter of the Italian clinical research community.

People tend to notice Domenico Criscuolo. Clearly remembering the time in London when he first met Criscuolo, Philip Ward (ACT’s European editor) describes that DIA meeting o­n clinical laboratory data. It was 1993, and several major companies had invested heavily in establishing central labs in Europe, without taking sufficient account of Europe’s geographical and cultural differences. Many representatives of sponsors and CROs were skeptical about central labs, but the central lab speakers “made a robust defense of how they can add value in the clinical trial process.”

For more information Cick Here

A. Ward, MSc, MRPharmS, G. O’Nally, RGN, MRPharmS, and G. Davies, PhD, MRPharmS
Hospital Pharmacist Vol 7 No 8 p210-213
September 2000

Applied Clinical Trials, Dec 1, 2002